Here, we introduce a multimodal platform based on P22 bacteriophage VLP integrating tumor targeting, ligand-mediated cellular internalization, delivery of CYP activity and photosensitizer payload, and the nanoscale combination of enzyme pro-drug activation therapy (EPT) and photodynamic therapy (PDT) for producing more potent, durable and highly specific anti-cancer response against ER+ breast cancer. The gene discussed is PPIG; the disease is neoplasm.